Korea Kyowa Kirin and Boryung Pharmaceutical Jointly Market Neutropenia Treatment

Korea Kyowa Kirin Neutropenia Treatment 'Gracin' Three Types

[Asia Economy Reporter Chunhee Lee] Kyowa Kirin Korea and Boryung Pharmaceutical are launching a co-promotion for neutropenia treatments.

The two companies announced on the 2nd that they have signed a co-promotion agreement to jointly market Kyowa Kirin's neutropenia treatments, Grasin (active ingredient 'Filgrastim') and Neulasta (active ingredient 'Pegfilgrastim').

Neutropenia treatments are supportive anticancer therapies used to alleviate the side effect of decreased neutrophil (a type of white blood cell) counts during chemotherapy in cancer patients, which lowers immunity. Grasin and Neulasta are first-generation and second-generation neutropenia treatments respectively, and both rank number one in prescriptions not only in the domestic market but also globally. According to the pharmaceutical market research firm IQVIA, last year, Grasin's prescription amount in Korea was approximately 21.5 billion KRW, and Neulasta's was about 25 billion KRW.

Through this agreement, Kyowa Kirin Korea plans to further focus on the hematologic cancer field while expanding the market share of Neulasta and Grasin by leveraging synergies with Boryung Pharmaceutical's diverse solid tumor portfolio. Boryung Pharmaceutical also aims to strengthen its position as a leading anticancer drug company by expanding its portfolio through the sales of leading supportive anticancer agents under this contract.

Kim Youngseok, Head of Boryung Pharmaceutical's Onco Division, said, “By introducing Grasin and Neulasta, we can provide excellent treatment options to more patients and healthcare professionals,” adding, “We plan to further increase market share based on Boryung Pharmaceutical's competitiveness and expertise accumulated in the anticancer drug field.” Lee Sangheon, President and CEO of Kyowa Kirin Korea, also stated, “We hope that by strengthening focus on the core areas of both companies, we can provide excellent products and services to more patients across various fields.”

This content was produced with the assistance of AI translation services.